Aurealis Therapeutics Partner Xbiome Receives IND Approval from China’s National Medical Products Administration for the Phase 2 Study with AUP-16 in Diabetic Foot Ulcers
Xbiome announced that its Phase 2 study with AUP-16 (AUP1602-C) in diabetic foot ulcer has officially obtained IND approval from the National Medical Products Administration (NMPA) and the study can be initiated in China. Public information shows that AUP1602-C is the first genetically engineered bacterial drug product to obtain clinical approval from the NMPA, setting […]
